Liya Wang1,
2, Juliya Kalinina3, Ruya Zhao2, Run Lin1,
2, Shaoxiong Wu4, Erwin Van Meir3, Hui Mao1,
2
1Department
of Radiology and Imaging Sciences, Emory University, Atlanta, GA, United
States; 2Center for Systems Imaging, Emory University, Atlanta,
GA, United States; 3Department of Neurosurgery, Emory University,
Atlanta, GA, United States; 4Department of Chemistry, Emory
University, Atlanta, GA, United States
Earlier studies suggest the mutation in isocitrate dehydrogenase 1/2 (IDH1/2) is a prognostic marker of glioma patients. The mutant enzyme gains a novel activity of producing the oncometabolite, R(-)-2-hydroxyglutarate (2HG), which can be detected in vivo and ex vivo by magnetic resonance spectroscopy. However, the role of 2HG in tumor development and progression remains to be better understood. This study investigated the relationships of 2HG concentrations obtained from magnetic resonance spectroscopic analysis with tumor progression features obtained from clinical pathology and radiology exams to explore the potential of using 2HG levels with as a biomarker for predicting brain tumor prognosis and responses to the treatment.